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Abstract
Background: Risk stratification and management of acute myocardial infarction patients continue to be challenging
despite considerable efforts made in the last decades by many clinicians and researchers. The aim of this study was to
investigate the metabolomic fingerprint of acute myocardial infarction using nuclear magnetic resonance spectroscopy
on patient serum samples and to evaluate the possible role of metabolomics in the prognostic stratification of acute
myocardial infarction patients.
Methods: In total, 978 acute myocardial infarction patients were enrolled in this study; of these, 146 died and 832
survived during 2 years of follow-up after the acute myocardial infarction. Serum samples were analyzed via high-
resolution 1H-nuclear magnetic resonance spectroscopy and the spectra were used to characterize the metabolic
fingerprint of patients. Multivariate statistics were used to create a prognostic model for the prediction of death within
2 years after the cardiovascular event.
Results: In the training set, metabolomics showed significant differential clustering of the two outcomes cohorts.
A prognostic risk model predicted death with 76.9% sensitivity, 79.5% specificity, and 78.2% accuracy, and an area
under the receiver operating characteristics curve of 0.859. These results were reproduced in the validation set,
obtaining 72.6% sensitivity, 72.6% specificity, and 72.6% accuracy. Cox models were used to compare the known
prognostic factors (for example, Global Registry of Acute Coronary Events score, age, sex, Killip class) with the
metabolomic random forest risk score. In the univariate analysis, many prognostic factors were statistically associated
with the outcomes; among them, the random forest score calculated from the nuclear magnetic resonance
data showed a statistically relevant hazard ratio of 6.45 (p = 2.16×10−16). Moreover, in the multivariate regression only
age, dyslipidemia, previous cerebrovascular disease, Killip class, and random forest score remained statistically
significant, demonstrating their independence from the other variables.
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Conclusions: For the first time, metabolomic profiling technologies were used to discriminate between patients with
different outcomes after an acute myocardial infarction. These technologies seem to be a valid and accurate addition
to standard stratification based on clinical and biohumoral parameters.
Keywords: Acute myocardial infarction, Nuclear magnetic resonance, Serum, Metabolomics, Biomarker, Prognosis,
Precision medicine
Background
Among cardiovascular diseases (CVDs), acute coronary
syndrome (ACS) represents the most common cause of
emergency hospital admission and it is associated with the
highest mortality and morbidity [1, 2]. The prognosis is
directly associated with timely initiation of revasculariza-
tion, and misdiagnosis or late diagnosis may have unfavor-
able clinical implications. Established risk stratification
tools such as the Global Registry of Acute Coronary
Events (GRACE) and the Thrombolysis In Myocardial In-
farction risk scores are derived from demographic, clinical,
laboratory, and electrocardiogram-related variables [3, 4].
These do not incorporate the use of newer biomarkers,
which could represent different pathophysiologic pro-
cesses and provide complementary prognostic informa-
tion, thereby improving risk stratification beyond
traditionally used variables.
Several studies have evaluated the potential clinical use-
fulness of new biomarkers able to identify patients who
had a poor outcome. In particular, high levels of inflam-
matory markers such as C-reactive protein and
interleukin-8 had long-term prognostic utility in patients
with ACS that undergone coronary revascularization [5,
6]. However, no conclusive and consistent data about the
prognostic utility of measuring inflammatory markers in
the early phase of ACS are available in the literature.
A number of studies have evidenced that a global ap-
proach, such as genomics, proteomics, or metabolomics,
may represent a valid strategy for improving current
knowledge about pathophysiological mechanisms and
for identifying ACS patients at high risk of secondary
atherothrombotic events or premature death.
Metabolomics is the accepted name for the -omic sci-
ence that deals with the characterization of the metabo-
lome, in turn defined as the whole set of metabolites in
a certain biological system, such as a cell, tissue, organ,
or entire organism [7]. The two leading analytical tech-
niques used to perform metabolomics are mass spec-
trometry (MS) and nuclear magnetic resonance (NMR)
spectroscopy. Both techniques yield information about
many different molecules in a single measurement, and
can be used to determine structures and concentrations
of metabolites [8]. Nevertheless, each technique has its
own strengths and limitations. MS overshadows NMR in
terms of numbers of compounds resolved (of the order of
103 [9]), with a sensitivity down to the picomolar and re-
quiring a very small volume of the biospecimen; however,
reproducibility is still a limitation of MS, which must be
overcome by an extensive and time-consuming use of
standards and quality control samples. NMR analysis is
high-throughput [7], and NMR data are highly reprodu-
cible [10] and intrinsically quantitative over a wide dy-
namic range, as demonstrated by numerous ring trials
performed by many different NMR laboratories [10].
NMR gives immediately qualitative and quantitative infor-
mation on around 102 different small molecules present in
a biological sample [11], and has already provided a global
picture of a wide range of metabolic processes underlying
complex and multifactorial diseases such as ACS.
Recently, the metabolomic approach has been applied
to identify a risk profile in heart failure patients [12–14],
atrial fibrillation patients [15], and diabetic patients [16].
In the setting of ACS, studies have characterized the meta-
bolic biosignature of myocardial ischemia [9, 17–20], iden-
tified altered signatures in lipid metabolism in patients
with angina or myocardial infarction with respect to con-
trol subjects [21], and identified microbial metabolites in
urine associated with coronary heart disease [22].
Risk stratification should identify individuals at high
risk who require more intensive therapy, or, conversely,
help avoid drug overuse and associated side effects in
patients with a favorable prognosis. In this framework,
the aim of the present study was to evaluate the impact
of the metabolomic fingerprint on the occurrence of car-
diovascular death in acute myocardial infarction (AMI)
patients after percutaneous coronary intervention.
Methods
This study was part of a collaborative project between
the Department of Medical and Surgical Critical Care of
the University of Florence and the Magnetic Resonance
Centre (CERM) of the University of Florence.
Study population
The study population comprised 978 out of 1496 pa-
tients admitted to the coronary units of the six hospitals
(five community hospitals and one university hospital,
the Careggi Hospital) of the Florence health district
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between April 2008 and April 2009, and enrolled in the
frame of the Florence Acute Myocardial Infarction-2
(AMI-Florence 2) registry [23]. In the present study, we
evaluated 978 patients (345 women and 633 men, me-
dian age 74 years); among them, 146 patients died within
2 years of the AMI event and 832 patients survived for
at least 2 years. The 2-year vital status was assessed by
consulting the registry office of the city of residence.
Mortality analysis was therefore censored at 24 months
after AMI or at date of death, whichever occurred earl-
ier. For this study, 35% of the AMI-Florence 2 popula-
tion was excluded because of the lack of a good quality
blood sample for the metabolomic analyses and/or be-
cause follow-up information was not available (Add-
itional file 1: Figure S1). However, according to a
standard power analysis [24] using a t test as the test
statistic, and fixing an alpha level of 0.05 for a significant
comparison, it was found that having 146 patients who
died and 832 patients who survived was enough to detect
small to medium effects (Cohen’s d ~0.25) with a statis-
tical power of 80%; furthermore, the training and valid-
ation sets separately showed adequate statistical power
(Cohen’s d = 0.54 and 0.29, respectively). Blood samples
were collected 24–48 h after percutaneous coronary inter-
vention (PCI) and overnight fasting. All information about
inclusion criteria and treatment of the patients are de-
tailed in Additional file 1: Supplementary material.
All subjects gave written informed consent. The study
(number 11/2008) complies with the Declaration of
Helsinki and was approved by the ethics committees of
the local health unit, the University of Florence, and
Careggi Hospital (19 March 2008).
NMR analyses
Samples were prepared following the standard protocols
detailed by Bernini et al. [25]. According to standard
practice [26], all spectra were acquired at 310 K using a
Bruker 600 MHz spectrometer (Bruker BioSpin), and for
each serum sample three one-dimensional 1H-NMR
spectra, namely nuclear Overhauser effect spectroscopy
(NOESY), Carr–Purcell–Meiboom–Gill (CPMG), and
Diffusion-edited spectra, were acquired, allowing the
selective detection of different molecular weight metabo-
lites. A detailed description of the sample preparation
and experiments is presented in the Additional file 1:
Supplementary material and Figure S1.
Each one-dimensional spectrum in the range 0.2–10.00
ppm was segmented into 0.02 ppm chemical shift bins
and the corresponding spectral areas were integrated
using AMIX software (version 3.8.4, Bruker BioSpin). The
region between 4.5 and 5.0 ppm containing the residual
water signal was removed and the dimension of the sys-
tem was reduced to 466 bins. The total spectral area was
calculated on the remaining bins and total area
normalization was carried out on the data prior to pattern
recognition.
Statistical analysis
Data analyses were performed using the open source
software R. For the demographic and baseline character-
istics, the t test was used for comparison between groups
and the chi-square test for comparison between categor-
ical variables.
For the multivariate data analyses of the NMR data,
the group of 978 patients was randomly split into two
independent cohorts [27]: a training set constituting 80
patients who survived and 40 who died, and a validation
set constituting all remaining patients (106 patients who
died and 752 who survived). A prospective power ana-
lysis [24] was employed to determine the minimum
number of patients (surviving and dead) that would need
to be retained in the training set to have a sufficiently
powered model, thereby maintaining a large fraction of
samples for the validation to guarantee a reliable estima-
tion of the performance of the model. After determining
that 80 patients who survived and 40 who died should
be retained in the training set, the allocation between
training and validation was performed randomly.
The initial analysis was restricted to the training set
and the first step was to establish if serum metabolomic
profiles could distinguish between patients who survived
and died within 2 years after the cardiovascular event.
For this purpose, a random forest (RF) classifier [28] was
built (considering for each sample the full spectrum;
thus, no choice of particular metabolite was performed).
The percentage of trees that assign one sample to a spe-
cific class can be inferred as a probability of class be-
longing [29–31]. For each patient, a score was created
that expressed the extent to which the serum metabolo-
mic profile appeared to be similar to the profile of one
of the patients who died, designated as the ‘RF risk
score’. For each patient, three RF scores were derived
using the three types of spectra acquired. For all calcula-
tions, the R package ‘Random Forest’ [32] was used to
grow a forest of 2,000 trees, using the default settings
(see Additional file 1: Supplementary material for further
details on the RF approach).
The next step was to test the hypothesis that a meta-
bolomic signature similar to that of one of the patients
who died would be predictive of death within 2 years
after the cardiovascular event. Using receiver operating
characteristics (ROC) analysis (“colAUC” function of the
R package “caTools”) and Harrell’s c index (“cindex”
function on the R package “dynpred”), the performances
of the RF risk scores were compared with the actual out-
come. To delineate high risk of death, a cut-off for the
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RF risk score was calculated in the training set that opti-
mized accuracy, sensitivity, and specificity, and the per-
formance of the model was subsequently tested in the
validation set.
The performances of the NOESY RF score were evalu-
ated by calculating a Cox proportional hazards regression
model [33] using the function “coxph” (R package “Sur-
vival”) and the model significance was assessed through a
likelihood-ratio test and by calculating the model con-
cordance. The independent prognostic capacity of the RF
risk score model in comparison with standard prognostic
features was also evaluated using Cox models. The per-
formance of NOESY RF scores was also compared with
the performance of the GRACE score and with a linear
combination of the two scores through ROC analysis,
Harrell’s c index, and univariate Cox models.
The spectral regions related to 23 metabolites, present
in concentrations above the detection limit (>1 μM) in
all samples (up to 30–40 different metabolites could be
quantified in each sample [34]), were assigned in the
CPMG NMR spectra by using matching routines of
AMIX 3.8.4 (Bruker BioSpin) in combination with the
BBIOREFCODE database (Bruker BioSpin) and the
freely available Human Metabolome DataBase [35], and
quantified. Metabolite quantification was determined by
software developed in-house based on standard
line-shape analysis methods. Using this approach, each
NMR region of interest was decomposed and deconvo-
luted into its component parts that corresponded to its
number of protons, and then integrated to obtain the
metabolite concentrations in arbitrary units (Additional
file 1: Figure S2). Wilcoxon signed-rank test [36] was
chosen to infer differences between the metabolites con-
centrations of the outcome groups on the biological as-
sumption that metabolite concentrations are not
normally distributed, and false discovery rate correction
was applied using the Benjamini–Hochberg method
[37]. An adjusted P-value < 0.05 was deemed significant.
Effect size using Cliff ’s delta [38] was calculated by
means of the R package “effsize”.
The statistical approach described above was also used
to build sex-specific statistical models based on NOESY
spectra.
NMR and clinical data are freely available in the
Open-Access Database Repository MetaboLights from
October 2017 with the accession number MTBLS395
(http://www.ebi.ac.uk/metabolights).
Results
Demographic and clinical characteristics of the enrolled
patients are shown in Table 1. The characteristics of
patients according to gender are also reported in
Additional file 1: Table S1.
NMR spectra
For each sample three NMR metabolomic profiles were
obtained using NOESY, CPMG, and Diffusion-edited
pulse sequences (Additional file 1: Figure S3). According
to the peculiar characteristics of each NMR experiment,
high and/or low molecular weight metabolites can be
detected. An exploratory principal component analysis
of the dataset is reported in Additional file 1: Figure S4.
Discrimination of the outcomes and the RF scores in the
training set
The metabolomic profiles of 80 patients who survived
and 40 who died (training set) were classified using the
RF classifier. The profiles showed significant differential
clustering, with good separation of the two groups using
each type of NMR spectra: NOESY (Fig. 1a), CPMG,
and Diffusion. Using ROC analyses, the areas under the
curve (AUC) obtained were 0.859 for NOESY spectra
(Fig. 1b), 0.857 for CPMG spectra, and 0.775 for Diffu-
sion editing spectra. NOESY and CPMG models showed
approximately the same performances, and the discrim-
ination between the two outcome groups can be as-
cribed to both low (mostly) and high molecular weight
metabolites. Thus, it was decided to use the NOESY
spectra in the further analyses because they contained
both high and low molecular weight metabolite
information.
A threshold of ≥ 0.454 for the NOESY RF score was
set to optimize accuracy, sensitivity, and specificity; this
optimized threshold yielded 76.9% (95% confidence
interval (CI) 76.5–77.3%) sensitivity, 79.5% (95% CI
78.4–80.6%) specificity, and 78.2% (95% CI 77.6–78.7%)
accuracy.
The goodness of fit of the NOESY RF model was calcu-
lated using a Cox proportional hazards regression model:
NOESY RF showed a hazard ratio of 7.4 (95% CI 3.51–
15.6) with a p-value of 3.45×10−09 calculated using the
likelihood-ratio test, and a concordance coefficient of 0.73.
Moreover, the NOESY RF model was robust with re-
spect to different strategies of model validation; indeed, a
mean AUC of 0.805 (95% CI 0.795–0.814) was obtained
with 100 cycles of classical Monte Carlo cross-validation
with data split 80 to 20% (training set, validation set). Fur-
thermore, our approach was robust with respect to the
origin of samples: only slight differences in the AUC were
obtained when using samples from the Careggi University
Hospital as the training set to build the RF model and
samples from all the other hospitals as the validation set
(and vice versa) (Additional file 1: Figure S5).
Outcome prediction by NOESY RF score in a validation set
of patients
The validation set (106 patients who died and 752 who
survived) was evaluated using an unsupervised analysis.
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Spectra of the validation samples were classified as ei-
ther ‘dead’ or ‘survivor’ using the optimized NOESY RF
risk score model derived from the training set. Compari-
son between metabolomic classification and actual out-
come demonstrated high correlation with an AUC of
0.801 (Fig. 1c). Using the threshold maximized in the
training set, we obtained 72.6% sensitivity, 72.6% specifi-
city, and 72.6% overall predicting accuracy.
The AUC calculated on the RF score was assessed for
significance against the null hypothesis of no prediction
accuracy in the data by means of 10,000 randomized
class-permutations tests: the estimated AUC obtained
after randomization was 0.570 (95% CI 0.569–0.571),
demonstrating the significance of our result (AUC 0.801,
p = 2.21×10−06).
The performances of the NOESY RF model in the val-
idation set was assessed using a Cox proportional haz-
ards regression model: NOESY RF showed a hazard
ratio of 6.16 (95% CI 4.02–9.44) with a p-value of
1.11×10−16 calculated using the likelihood-ratio test, and
a concordance coefficient of 0.71.
Comparison of the NOESY RF score with known prognostic
factors and the GRACE score
The known prognostic factors age, sex, previous CABG,
previous PCI, heart failure, atrial fibrillation, cerebrovas-
cular disease, diabetes, creatinine concentration, Killip
class, and ACS classification were compared with the
NOESY RF risk score, calculated on the entire dataset,
in univariate and multivariate Cox regression analyses.
The results are displayed in Table 2.
In the univariate analysis, many prognostic factors
were statistically associated with the outcomes, among
them the NOESY RF score showed a Cox hazard ratio of
6.45. In the multivariate analysis, only age, dyslipidemia,
hypertension, previous cerebrovascular disease, Killip
Table 1 Demographic and clinical characteristics
Survived (n=832) Died (n=146) p-value
Demographic characteristics,
Age (years), median (IQR) 72 (62–80) 82 (78–83) < 2.20×10−16
Female sex, n (%) 278 (33.4) 67 (45.9) 4.86×10−03
Cardiovascular risk factors, n (%)
Hypertension 537 (64.5) 104 (71.2) 1.21×10−01
Dyslipidemia 294 (35.3) 32 (21.9) 3.55×10−03
Current smokers 226 (27.2) 20 (13.7) 1.45×10−04
Ex-smokers 21 (2.5) 8 (5.5) 4.01×10−01
CAD 220 (26.4) 17 (11.6) 5.03×10−04
Diabetes 197 (23.7) 61 (41.8) 6.32×10−06
Medical history, n (%)
Myocardial infarction 164 (19.7) 48 (32.9) 5.23×10−04
Angina, onset > 1 month 119 (14.3) 24 (16.4) 8.96×10−01
Angina, onset ≤ 1 month 149 (17.9) 15 (10.3) 3.78×10−02
CABG 41 (4.9) 10 (6.8) 4.39×10−01
PCI 136 (16.3) 32 (21.9) 1.20×10−01
Chronic heart failure 33 (4.0) 26 (17.8) 2.62×10−10
Atrial fibrillation 42 (5.0) 21 (14.4) 4.60×10−05
Cerebrovascular disease 50 (6.0) 28 (19.2) 1.28×10−07
Presentation features
ACS classification, STEMI, n (%) 343 (41.2) 35 (24.0) 1.15×10−04
Killip II–IV, n (%) 114 (13.7) 61 (41.8) 6.33×10−16
Creatinine > 1.2 mg/dL, n (%) 129 (15.5) 54 (37.0) 4.08×10−09
Heart rate (bpm), median (IQR) 80 (67–91) 90 (80–105) 3.66×10−06
Positive peak troponine maximum, n (%) 804 (96.6) 143 (97.9) 6.98×10−01
Positive peak CK-MB maximum, n (%) 422 (50.7) 50 (32.2) 1.88×10−03
GRACE score > 118, n (%) 687 (82.6) 123 (84.2) 1.62×10−01
CAD coronary artery diseases, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, ACS acute coronary syndrome, STEMI ST-segment
elevation myocardial infarction, CK-MB creatine kinase-MB, GRACE Global Registry of Acute Coronary Events
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class, and NOESY RF score remained statistically signifi-
cant, demonstrating their independence with respect to the
other variables. The smoker’s paradox, already described
by other studies [39], was also observed in this cohort.
The performance of the NOESY RF score in predicting
2-year outcomes was also compared with the perform-
ance of the GRACE hospital discharge risk score [40] for
those patients for whom all clinical parameters needed
to calculate the GRACE score were available (84.5% of
patients). The results (Harrell’s c index and AUC) dem-
onstrated that the NOESY RF score performed slightly
better in both the training and the validation sets
(Table 3, Fig. 2), confirming that the metabolomic ap-
proach described here could be useful for risk stratifica-
tion in the setting of post-AMI patients. Moreover, the
score obtained by a linear combination of the two scores
(NOESY RF + GRACE scores) was calculated (Table 3,
Fig. 2); the combined model showed statistically improved
results (analysis of variance test p-value < 0.01 after
Bonferroni correction) with respect to the two separate
scores in both the training and validation sets. A compari-
son of these two scores with the NOESY RF score is in-
cluded in the Cox regression analyses in Table 2.
Using ROC analyses, the performance of the NOESY
RF and GRACE scores was tested against some
well-known parameters that are commonly measured in
the clinical practice (age, heart frequency, diastolic pres-
sure, systolic pressure, creatinine concentration, gly-
cemia, platelets). Training and validation sets were
considered separately and only data from patients for
whom all the clinical parameters were available were in-
cluded (80.5% of the entire cohort). As shown in Fig. 3,
our score showed the best performances in predicting
death within 2 years from the cardiovascular event both
in training and validation sets (AUC 0.837 and 0.797, re-
spectively); age showed comparable results (AUC 0.828
and 0.747) and the GRACE score presented slightly
worse results (AUC 0.809 and 0.75).
The performance of our approach was also tested by
dividing patients in two distinct subgroups of patients ac-
cording to AMI severity (ST-segment elevation myocar-
dial infarction (STEMI) and non-STEMI). The results
demonstrated that our approach is marginally affected by
these two subcategories (Additional file 1: Supplementary
material and Figure S6).
Metabolites analysis
An analysis of the NMR spectra was conducted to identify
which metabolites were statistically different between
patients who died and survived. All patients (training and
validation sets) were included in the analysis. The
following 23 metabolites were unambiguously assigned
and quantified in the spectra: acetate, acetone, alanine, cit-
rate, creatine, creatinine, formate, glucose, glutamate,
glutamine, glycine, histidine, isobutyrate, isoleucine, lac-
tate, leucine, mannose, methionine, phenylalanine, proline,
tyrosine, valine, and 3-hydroxybutyrate. We observed that
patients who died were characterized by significantly (ad-
justed p-value < 0.05) higher levels of 3-hydroxybutyrate,
proline, creatinine, acetate, acetone, formate, and man-
nose, and significantly lower levels of valine and histidine
(Additional file 1: Table S2).
Metabolite analyses replicated separately in the train-
ing and validation sets are provided in Additional file 1:
Figure S7.
Fig. 1 Clusterization of serum metabolomic profiles and comparisons between metabolomic classification and outcomes in the training set and
the validation set. a Discrimination between patients who survived (blue dots, n = 80) and died (red dots, n = 40) using the Random Forest
classifier on nuclear Overhauser effect spectroscopy (NOESY) spectra in the training set. b, c The receiver operator characteristic curves and the
area under the curve (AUC) scores are presented for the training set (b) and validation set (c)
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Table 3 Comparison between GRACE score, NOESY RF score and a linear combination of NOESY RF and GRACE scores
(GRACE + NOESY RF scores)
GRACE score NOESY RF score GRACE + NOESY RF scores
Training set
AUC (95% CI) 0.815 (0.794-0.820) 0.859 (0.858-0.860) 0.875 (0.864-0.885)
Harrell’s c index 0.776 (0.761-0.781) 0.806 (0.805-0.809) 0.828 (0.821-0.835)
Validation set,
AUC 0.756 (0.754-0.758) 0.801 (0.800-0.802) 0.823 (0.822-0.825)
Harrell’s c index 0.740 (0.744-0.747) 0.789 (0.789-0.790) 0.809 (0.808-0.810)
GRACE Global Registry of Acute Coronary Events, NOESY nuclear Overhauser effect spectroscopy, RF random forest, AUC area under the receiver operating
characteristic, CI confidence interval
Table 2 Association with the outcome: unadjusted and adjusted hazard ratios
Hazard ratio (univariate) p-value Hazard ratio (multivariate) p-value
Age
68–79 4.63 2.24×10−04 2.09 1.45×10−01
> 79 12.86 8.90×10−11 3.87 8.33×10−03
Male sex 0.64 1.35×10−02 0.96 8.72×10−01
Hypertension 1.34 1.47×10−01 0.53 1.98×10−02
Dyslipidemia 0.55 7.16×10−03 0.38 7.91×10−03
Smoking habits
Yes 0.43 1.67×10−03 1.25 5.04×10−01
Ex-smokers 1.13 7.95×10−01 4.14×10-08 9.95×10−01
CAD 0.41 2.00×10−03 0.99 9.86×10−01
Previous CABG 1.16 7.10×10−01 1.92 2.61×10−01
Previous PCI 1.28 2.69×10−01 1.66 9.64×10−02
Heart failure 3.67 1.07×10−07 1.81 8.98×10−02
Atrial fibrillation 2.37 7.03×10−04 1.30 4.52×10−01
Cerebrovascular disease 3.17 4.10×10−07 1.96 2.67×10−02
Diabetes 1.99 1.83×10−04 1.05 8.58×10−01
Creatinine (>1.2 mg/dL) 2.89 8.70×10−09 1.29 3.37×10−01
Killip class
II 3.43 4.89×10−09 1.77 4.26×10−02
III 4.87 9.12×10−10 3.31 4.76×10−04
ACS classification
STEMI 0.49 1.34×10−03 0.72 3.00×10−01
NOESY RF risk score
≥ 0.454 6.45 2.16×10−16 3.71 2.36×10−05
GRACE score#
≥ 170 6.05 3.76×10−06 – –
NOESY RF + GRACE#
≥ 7.7 9.33 2.16×10−16 – –
Correlation with the outcome for prognostic features and RF risk score in the full dataset, using univariate and multivariate analysis. Age split into tertiles. In the
multivariate, hazard ratios of all the variable were included together in the analysis
CAD coronary artery diseases, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, ACS acute coronary syndrome, STEMI ST-segment
elevation myocardial infarction, NOESY nuclear Overhauser effect spectroscopy, RF random forest, GRACE Global Registry of Acute Coronary Events
#These variables were not included in the multivariate analysis due to the strong co-linearity between GRACE score and the other clinical variables [66]
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Fig. 2 Receiver operator characteristic curve and area under the curve (AUC) of nuclear Overhauser effect spectroscopy (NOESY) random forest
(RF) score, Global Registry of Acute Coronary Events (GRACE) score, and linear combined score of NOESY RF and GRACE score are reported for
the a training and b validation sets
Fig. 3 Nuclear Overhauser effect spectroscopy (NOESY) random forest (RF) score, Global Registry of Acute Coronary Events (GRACE) score, and
clinical parameters receiver operator characteristic (ROC) curves for the a training and b validation sets. The ROC curves and the area under the
curve scores are presented for NOESY RF score, GRACE score, age, heart frequency, diastolic pressure, systolic pressure, glycemia, creatinine, platelets,
troponine maximum, and creatine kinase-MB maximum
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Sex-specific RF models
The presence of sex-specific differences in human me-
tabolism is well known and the NMR metabolomics is
sensitive to these differences [41, 42]. Therefore, we de-
cided to build different RF models for women and men
to obtain an outcome clusterization and prediction un-
biased by sex.
For each sex-specific group using the RF classifier, the
metabolomic NOESY one-dimensional profiles of 60 pa-
tients who survived and 30 who died were randomly se-
lected for classification. Both sex models showed
significant differential clustering, with a good separation of
the two outcome groups (Additional file 1: Figure S8a, d).
Using the NOESY NMR spectra of the female and
male cohorts separately, the RF classifier discriminated
patients who died from those who survived in the train-
ing set with an AUC of 0.786 and 0.834, respectively
(Additional file 1: Figure S8b, e). Thresholds of ≥ 0.46
for the female cohort and ≥ 0.476 for the male cohort
were set in the training set by optimizing accuracy, sen-
sitivity, and specificity. The results for both cohorts are
shown in Additional file 1: Table S3.
When applying these models to the validation set of
female and male cohorts, we obtained an AUC of 0.782
and 0.821, respectively (Fig. 3c, f ). When using the
threshold maximized in the training set, we obtained an
overall accuracy of 74.7% and 73.4% for predicting the
likelihood of outcome in female and male cohorts, re-
spectively (Additional file 1: Table S3).
On analyzing the spectra of the female and male co-
horts, we observed that female patients who died were
characterized by higher levels of creatinine, whereas
male patients who died were characterized by higher
levels of 3-hydroxybutyrate, proline, creatinine, and for-
mate, and significantly lower levels of histidine and val-
ine (Additional file 1: Figure S7b, c).
Discussion
After the acute phase of an AMI, for which management
is strictly defined by the European Society of Cardiology
Guidelines [43, 44], patients remain at increased risk of
secondary atherothrombotic events, including recurrent
ACS events and stroke, and continue to face a high risk
of premature death not only in the immediate future but
also in the following years [45, 46]. For these reasons,
the identification of a metabolomic fingerprint able to
identify patients who are at increased risk of death might
allow clinicians to tailor medical treatments and inter-
ventions according to patients’ overall risk: high-risk
patients could be targeted with more intensive pharma-
cological treatments (that is, with the highest tolerated
statin dosage or more aggressive antiplatelet treatments),
and more intensive follow-up programs could be
planned with clinical reevaluation at shorter time inter-
vals (that is, monthly instead of the standard visits at 1,
6, and 12 months). In AMI patients enrolled in the
AMI-Florence 2 study, we found a metabolic fingerprint
which was able to discriminate patients who died within
2 years from the cardiovascular event from survivors
with high accuracy (AUC 0.859), and this result was du-
plicated in a validation set (AUC 0.801). We also built
sex-specific RF models and found that the male model
was better able to predict outcomes (male: AUC 0.834;
female: AUC 0.786), which was confirmed in the valid-
ation set. To the best of our knowledge, this is the first
study to assess the capability of a metabolomic assay to
predict mortality in the setting of AMI.
A metabolic fingerprint can be deemed as a holistic
super-biomarker with a discriminative and predictive
power undoubtedly higher than that of the sum of the
few quantified metabolites [47]. AMI, as with the major-
ity of human diseases, has a multifactorial etiology and a
complex physiopathology that concurrently alters several
metabolic pathways [48]. Therefore, the metabolic fin-
gerprint, composed by superimposing all the visible sig-
nals of the low and high molecular weight endogenous
metabolites, represents an optimal level at which to
analyze pathological changes in biological systems [49];
indeed, it takes into account all metabolite variations,
even slight ones.
The NOESY RF score, based on the metabolic finger-
print here presented, was independent from the classical
clinical parameters and the widely used GRACE score,
and achieved better results in predicting all-cause death
within 2 years after AMI when considering both Cox
models and ROC analyses. It is worth of mentioning that
age was a very good predictor of mortality in our dataset;
in particular, it proved to be better than even the GRACE
score in our training set. Older patients showed the worst
clinical conditions, with a higher percentage of heart fail-
ure, atrial fibrillation, previous cerebrovascular diseases,
and diabetes. These parameters are not included in the
GRACE score model, and could explain why age per-
formed very well as a predictor in our cohort.
Although our study has several strengths, including
the number of patients studied, the long-term follow-up
(2 years), and the analysis replication in a validation set,
some limitations should also be mentioned. First, sample
collections were done exclusively in the acute phase of
the disease, impairing the acquisition of data correlated
to the biochemical mechanisms of the transition to the
quiescent phase. Owing to the importance of this aspect,
further efforts in this direction are required. Second,
even though the data were replicated in a validation set,
a totally independent cohort for validation is lacking.
However, before attempting to replicate these findings in
very large multicenter studies, common standard
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operating procedures are required for sample collection
and storage, otherwise samples collected in different
centers will not be comparable. Our group is strongly
committed to this, and have contributed to the develop-
ment of the optimal pre-analytical procedures for meta-
bolomics [25]. Finally, NMR is less sensitive than MS
(although it is more suitable for metabolic fingerprint-
ing), and thus only a limited number of metabolites have
been found to be statistically significant. Specifically, we
found that patients who died were characterized by sig-
nificantly higher levels of 3-hydroxybutyrate, proline,
creatinine, acetate, acetone, formate, and mannose, and
significantly lower levels of valine and histidine.
Lifestyle and the medication administered to a patient
influence the molecular signatures in plasma and serum
samples, and the relative metabolite concentrations reflect
tissue lesions and organ dysfunctions. In this framework,
previous studies have underlined the usefulness of meta-
bolomics of serum and plasma in determining the individ-
ual’s disease risk, prognosis, and therapeutic options in
different clinical settings [29, 30, 50, 51]. For instance, sera
of heart failure patients carries a strong signature of the
disease, allowing the estimation of heart failure-related
metabolic disturbance and possessing a better prognostic
value than conventional biomarkers [13, 51].
In a prospective study of three population-based co-
horts from Finland that were free of CVD at baseline
[52], a metabolomic analysis evidenced that circulating
phenylalanine, monounsaturated fats, and polyunsatur-
ated fatty acids were as strongly predictive of cardiovas-
cular risk as the conventional lipid risk factors, and were
markers of CVD onset during a long-term follow-up
(more than a decade). In our study, we did not find any
role for these metabolites in predicting mortality. How-
ever, the different study populations (CVD- free vs. AMI
patients) with different lifestyle and dietary habits may
explain the different molecular signatures.
The usefulness of the metabolomic approach was also
demonstrated in a general cohort of patients at risk for
cardiovascular events undergoing cardiac catheterization
[53]; at baseline, plasma metabolomic profiles independ-
ently predicted cardiovascular death after adjustment for
multiple clinical covariates. In this study, a significant
predictive role was demonstrated for five metabolite fac-
tors (medium-chain acylcarnitines, short-chain dicarbox-
ylacylcarnitines, long-chain dicarboxylacylcarnitines,
branched-chain amino acids, and fatty acids). We con-
sistently found in the present study that higher levels of
valine were a protective factor in AMI patients. At vari-
ance with our study, increased concentrations of
branched-chain amino acids levels have been shown in
coronary artery patients compared with control subjects
[54], and high levels of these essential amino acids sig-
nificantly correlated with the severity of coronary artery
disease (CAD) [55]. However, these studies were
case-control studies and did not evaluate CAD patients
in the acute phase of the disease. The pathways of the
branched amino acids in humans are very complex and
it is likely that in ACS patients an altered metabolic
pathway for these amino acids represents a prognostic
risk factor.
Our study, performed in a large sample population of
AMI patients followed for 2 years, provided new data
about the role of high 3-hydroxybutyrate circulating levels
on post-AMI mortality. A previous study that evaluated
the ketone bodies in the urine of five ACS patients
demonstrated that ketone bodies, and particularly
3-hydroxybutyrate, were altered during the acute event
[56]. Furthermore, high levels of 3-hydroxybutyrate have
been associated with high prevalence of heart failure and
diabetes [57]. In insulin deficiency, when the release of
free fatty acids from adipose tissues exceeds the capacity
of the tissues to metabolize them, severe and potentially
fatal diabetic ketoacidosis can occur in which levels of
3-hydroxybutyrate in the blood can reach up to 25 mM
[58]. A recent study has also demonstrated a significant
increase of serum ketone bodies in response to
angioplasty-induced ischemia performed in patients with
stable angina, and it has been hypothesized that these
metabolic changes could be a response to reperfusion oxi-
dative stress and may play a key role in free radical
homeostasis during ischemia-reperfusion injury [59].
However, it remains unclear whether the elevation of
ketone bodies represents an adaptive mechanism re-
quired to maintain cell metabolism or if it actually
contributes to disease progression and, thus, the
worsening of the prognosis.
Furthermore, it is worth of mentioning that formate
has already been proposed as a possible biomarker of
ACS [60].
As expected, patients with worst prognosis showed
higher level of serum creatinine, a well-known marker of
renal insufficiency. It has already been demonstrated
that elevated serum levels of creatinine on admission are
associated with impaired myocardial flow and poor
prognosis for 1-year mortality [61, 62].
Previous studies evidenced an interaction between sex
and adverse cardiovascular events in CAD patients [63–
65], with myocardial infarction morbidity and mortality
higher in women than in men. Consistently, our results
demonstrated a higher prevalence of mortality in women
than in men (19.4% vs. 12.5%). The excess risk of mor-
tality in women could be ascribed to the differences in
cardiovascular risk factor, that is, age, hypertension, dia-
betes, and co-morbidities prevalence. Accordingly, in
our study, women showed a higher median age and
higher prevalence of hypertension, atrial fibrillation, and
heart failure with respect to men.
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Building sex-specific models enabled us to improve
the outcome prediction in the male cohort, but not in
the female one. Thus, the male metabolic fingerprint
seems to show a higher association with cardiovascular
mortality than the female one. However, the female co-
hort was smaller than the male cohort and this may have
affected the predictive capability of the model; therefore,
larger cohorts of patients are needed to build robust
sex-specific models.
Conclusions
Our data support the usefulness of the metabolomic ap-
proach for identifying a more precise risk profile in AMI
patients. Metabolomic analysis by NMR enables fast, ap-
proachable, and reproducible characterization of the
AMI metabolic fingerprint associated with a poor prog-
nosis, improving the cardiovascular risk assessment be-
yond that achieved by established risk factors, and
identifying those patients who need to undergo a very
early and aggressive treatment. Thus, metabolomics
could represent a valid addition to the already estab-
lished risk stratification tools. Further, as demonstrated
by the combination of the NOESY RF scores with the
Grace score, metabolomics, in combination with clas-
sical tests, is able to significantly improve risk classifica-
tion over the two separate scores.
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